Published in Cell Cycle on March 25, 2009
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol (2010) 4.94
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis. Lab Invest (2017) 0.75
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature (2008) 5.59
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol (2010) 4.94
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet (2009) 4.52
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature (2010) 3.70
Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol (2011) 3.56
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51
Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol (2007) 3.47
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
The origins of medulloblastoma subtypes. Annu Rev Pathol (2008) 3.36
Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol (2009) 3.32
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell (2009) 3.11
The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res (2009) 3.03
Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell (2011) 2.87
beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol (2005) 2.84
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol (2011) 2.82
Dual and opposing roles of primary cilia in medulloblastoma development. Nat Med (2009) 2.73
Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle (2006) 2.37
A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res (2010) 2.37
Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol (2012) 2.34
A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell (2012) 2.15
The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev (2005) 2.14
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol (2010) 2.04
Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol (2012) 2.01
Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol (2011) 2.01
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell (2011) 1.78
Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res (2004) 1.67
Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol (2007) 1.67
Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior. Brain Pathol (2007) 1.59
ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res (2002) 1.58
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol (2010) 1.48
PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet (2003) 1.46
A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol (2010) 1.46
Defining future directions in spinal cord tumor research: proceedings from the National Institutes of Health workshop. J Neurosurg Spine (2010) 1.45
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin Cancer Res (2010) 1.43
Ependymoblastoma: dear, damned, distracting diagnosis, farewell!*. Brain Pathol (2008) 1.40
Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma. Genes Chromosomes Cancer (2006) 1.35
MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol (2011) 1.33
Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res (2011) 1.33
Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS One (2009) 1.33
Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol (2011) 1.32
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol (2014) 1.28
DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol (2013) 1.27
The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg (2009) 1.27
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res (2009) 1.25
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res (2009) 1.24
Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res (2013) 1.23
Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro Oncol (2010) 1.22
Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Eur J Cancer (2006) 1.22
Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol (2010) 1.20
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res (2013) 1.20
Young age may predict a better outcome for children with diffuse pontine glioma. Cancer (2008) 1.18
The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. Brain Res Mol Brain Res (2004) 1.17
Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model. Cancer Res (2011) 1.17
Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol (2012) 1.16
What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol (2003) 1.16
RAF gene fusion breakpoints in pediatric brain tumors are characterized by significant enrichment of sequence microhomology. Genome Res (2011) 1.14
Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. Cell Cycle (2009) 1.13
Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis (2003) 1.13
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol (2013) 1.12
Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol (2003) 1.11
MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J Cell Physiol (2010) 1.10
Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro Oncol (2011) 1.10
Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro Oncol (2008) 1.07
Bmi1 is required for Hedgehog pathway-driven medulloblastoma expansion. Neoplasia (2008) 1.04
Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis. Cancer (2009) 1.03
Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res (2009) 1.02
PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol (2013) 1.00
Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int J Cancer (2006) 1.00